Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals
(NQ:
SYRS
)
1.930
-0.020 (-1.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Sidoti Events, LLC's Virtual June Small-Cap Conference
June 13, 2023
Via
ACCESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
June 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Syros Pharmaceuticals's Earnings Outlook
May 09, 2023
Via
Benzinga
Syros Pharmaceuticals's Return On Capital Employed Overview
March 08, 2023
Via
Benzinga
Syros Pharmaceuticals's Earnings Outlook
March 01, 2023
Via
Benzinga
Analyst Expectations for Syros Pharmaceuticals's Future
January 05, 2023
Via
Benzinga
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 25, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 10, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals's Return On Capital Employed Overview
December 23, 2022
Via
Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 04, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 31, 2023
On Friday, 93 stocks made new 52-week lows.
Via
Benzinga
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday
March 03, 2023
Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in...
Via
Benzinga
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences in March
February 28, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
February 23, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
January 26, 2023
Via
Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
January 26, 2023
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
Syros Announces Clinical Updates and 2023 Strategic Priorities
January 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
December 20, 2022
On Tuesday, 298 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
December 19, 2022
On Monday, 297 companies reached new 52-week lows.
Via
Benzinga
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
December 12, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
December 10, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
December 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.